Physician profile
Thomas Parry Hooker
NPI 1437185204
$2,704.84
in general payments reported to CMS, 2019-2025
23 companies · $32.48 in 2025
The $32.48 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $489 · 2021: $529 · 2022: $607 · 2023: $72.21 · 2024: $34.71 · 2025: $32.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.68 · Education: $48.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.68 |
| Education | $48.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.87 | 2019-2022 | |
| Glaxosmithkline, LLC. | $421.40 | 2019-2022 | |
| Electromed, INC. | $351.55 | 2019-2024 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $274.58 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $224.87 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $181.09 | 2019-2022 | |
| Philips North America LLC | $149.76 | 2019-2022 | |
| Grifols USA, LLC | $117.18 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $103.95 | 2019-2020 | |
| United Therapeutics Corporation | $67.85 | 2022-2023 | Tyvaso |
| Insmed, INC. | $63.18 | 2019-2025 | Arikayce |
| Mylan Specialty L.P. | $55.92 | 2020-2022 | |
| Genentech USA, INC. | $40.83 | 2019 | |
| Merck Sharp & Dohme LLC | $36.31 | 2019 | |
| Pulmonx Corporation | $29.67 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inogen, INC. | $24.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.77 | 2020 | |
| Jazz Pharmaceuticals INC. | $22.48 | 2021 | |
| Veran Medical Technologies, INC. | $19.63 | 2020 | |
| Pfizer INC. | $18.21 | 2022 | |
| Olympus America INC. | $14.55 | 2022 | |
| Advanced Respiratory, INC | $12.59 | 2019 | |
| Fisher & Paykel Healthcare INC | $10.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Hooker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.